The 5 analysts offering 12-month price forecasts for Catalyst Pharmaceuticals Inc have a median target of 25.00, with a high estimate of 27.00 and a low estimate of 15.50. The median estimate represents a +76.80% increase from the last price of 14.14.
The current consensus among 5 polled investment analysts is to Buy stock in Catalyst Pharmaceuticals Inc. This rating has held steady since August, when it was unchanged from a Buy rating.Move your mouse over past months for detail
Earnings and Sales Forecasts
Earnings per Share $0.34
Reporting Date Mar 13
Earnings per Share
Move your mouse over a quarter or year to see how estimates have changed over time.